Co-transplantation of stromal cells interferes with the rejection of allogeneic islet grafts.
Side effects associated with current immunosuppressive therapy complicate the use of islet transplantation as a treatment for type 1 diabetes. Multipotent mesenchymal stromal cells (MSCs) have demonstrated immunomodulatory activity. The purpose of this study was to investigate whether a murine stromal cell line affects graft rejection in a fully major histocompatibility complex (MHC)-mismatched islet transplant model. We show that stromal cells have an inhibitory effect on T cell proliferation in vitro, and that they slow down the rejection of allogeneic islets. These findings indicate a possibility to use MSCs as a treatment to prolong the survival of islet grafts.
Jacobson
Stella
S
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Kumagai-Braesch
Makiko
M
Tibell
Annika
A
Svensson
Mattias
M
Flodström-Tullberg
Malin
M
D000818:Animals; D049109:Cell Proliferation; D002478:Cells, Cultured; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000502:physiology; D007165:Immunosuppression Therapy / Q000379:methods*; D016381:Islets of Langerhans Transplantation / Q000379:methods* / Q000502:physiology; D008213:Lymphocyte Activation / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D017154:Stromal Cells / Q000502:physiology* / Q000637:transplantation*; D013601:T-Lymphocytes / Q000276:immunology / Q000502:physiology; D014184:Transplantation, Homologous